Skip to content
2000
Volume 19, Issue 2
  • ISSN: 2772-2708
  • E-ISSN: 2772-2716

Abstract

Psoriasis, a chronic inflammatory skin disorder affecting approximately 2% of the global population, is characterized by a complex interplay of immunological dysregulation, genetic predisposition, and environmental factors. This review explores the dynamic mechanisms underlying psoriasis, highlighting the role of T lymphocytes in targeting healthy skin cells, leading to inflammation and the formation of characteristic white scaly patches on various body parts. Over the past 15 years, significant strides in unraveling the origins of psoriasis have paved the way for the development of precise and highly effective treatments. Key insights into the pathogenesis, particularly the dominance of interleukin-17 (IL-17) and interleukin-23 (IL-23), have shaped therapeutic strategies to mitigate chronic inflammatory disorders. Notably, various therapies employing different mechanisms of action, including interleukin blockers and tumor necrosis factor-alpha (TNF-α) inhibitors, have emerged as valuable options for psoriasis management. This review provides a comprehensive overview of the current understanding of psoriasis pathophysiology and highlights advanced therapeutic approaches that are widely accessible. The focus extends to emerging targeted drugs, such as netakimab, which functions as an interleukin-17 blocker, currently undergoing clinical trials for psoriasis treatment. By synthesizing the latest research findings, this article aims to contribute to the knowledge base surrounding psoriasis, offering clinicians and researchers valuable insights into the evolving landscape of psoriasis treatment modalities.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raiad/10.2174/0127722708300943240724051518
2024-08-02
2025-10-03

  • From This Site

    /content/journals/raiad/10.2174/0127722708300943240724051518
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HaliouaB. A history of psoriasis.Ann Dermatol Venereol.2019146216016510.1016/j.annder.2018.11.001
     [Google Scholar]
  2. KaurI. HandaS. KumarB. Natural history of psoriasis: a study from the Indian subcontinent.J Dermatol.1997244230234
     [Google Scholar]
  3. NairP.A. BadriT. Psoriasis.StatPearlsTreasure IslandIn: StatPearls Publishing2023
     [Google Scholar]
  4. BoehnckeW.H. SchönM.P. Psoriasis.Lancet2015386999798399410.1016/S0140‑6736(14)61909‑726025581
     [Google Scholar]
  5. KumarD. RajguruJ.P. MayaD. SuriP. BhardwajS. PatelN. Update on psoriasis: A review.J. Family Med. Prim. Care202091202410.4103/jfmpc.jfmpc_689_1932110559
     [Google Scholar]
  6. KocaT.T. KocaT.T. BaglanT. A short summary of clinical types of psoriasis.North. Clin. Istanb.201631798210.14744/nci.2016.1602328058392
     [Google Scholar]
  7. JiangY. ChenY. YuQ. ShiY. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.BioDrugs2023371355510.1007/s40259‑022‑00569‑z36592323
     [Google Scholar]
  8. GoodherhamM.J PappK.A Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.J Eur Acad Dermatol Venereol.202332711111119
     [Google Scholar]
  9. DikaE. BardazziF. BalestriR. MaibachH.I. Environmental factors and psoriasis.Curr. Probl. Dermatol.20073511813510.1159/00010641917641494
     [Google Scholar]
  10. ChenL. LiJ. ZhuW. KuangY. LiuT. ZhangW. ChenX. PengC. Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies.Front. Microbiol.20201158972610.3389/fmicb.2020.58972633384669
     [Google Scholar]
  11. ZangC. LiuJ. MaoM. ZhuW. ChenW. WeiB. Causal Associations Between Gut Microbiota and Psoriasis: A Mendelian Randomization Study.Dermatol. Ther. (Heidelb.)202313102331234310.1007/s13555‑023‑01007‑w37653234
     [Google Scholar]
  12. RoussetL. HaliouaB. Stress and psoriasis.Int. J. Dermatol.201857101165117210.1111/ijd.1403229729012
     [Google Scholar]
  13. SwanbeckG. InerotA. MartinssonT. WahlströmJ. A population genetic study of psoriasis.Br. J. Dermatol.19941311323910.1111/j.1365‑2133.1994.tb08454.x8043420
     [Google Scholar]
  14. YamanakaK. YamamotoO. HondaT. Pathophysiology of psoriasis: A review.J. Dermatol.202148672273110.1111/1346‑8138.1591333886133
     [Google Scholar]
  15. HandaS. MahajanR. Pathophysiology of psoriasis.Indian J. Dermatol. Venereol. Leprol.2013797110.4103/0378‑6323.11550523974689
     [Google Scholar]
  16. IwakuraY. IshigameH. SaijoS. NakaeS. Functional specialization of interleukin-17 family members.Immunity201134214916210.1016/j.immuni.2011.02.01221349428
     [Google Scholar]
  17. ChiricozziA. Guttman-YasskyE. Suárez-FariñasM. NogralesK.E. TianS. CardinaleI. ChimentiS. KruegerJ.G. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.J. Invest. Dermatol.2011131367768710.1038/jid.2010.34021085185
     [Google Scholar]
  18. TeunissenM.B.M. BosJ.D. KoomenC.W. de Waal MalefytR. WierengaE.A. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes.J. Invest. Dermatol.1998111464564910.1046/j.1523‑1747.1998.00347.x9764847
     [Google Scholar]
  19. HawkesJ.E. ChanT.C. KruegerJ.G. Psoriasis pathogenesis and the development of novel targeted immune therapies.J. Allergy Clin. Immunol.2017140364565310.1016/j.jaci.2017.07.00428887948
     [Google Scholar]
  20. SchönM.P. ErpenbeckL. The Interleukin-23/Inteleukin-17 axis links adaptive and innate immunity in psoriasis.Front. Immunol.20189132310.3389/fimmu.2018.0132329963046
     [Google Scholar]
  21. O’SheaJ.J. GadinaM. Selective Janus kinase inhibitors come of age.Nat. Rev. Rheumatol.2019152747510.1038/s41584‑018‑0155‑930622297
     [Google Scholar]
  22. Jorn BovenschenH. van de KerkhofP.C. van ErpP.E. WoestenenkR. JoostenI. KoenenH.J.P.M. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.J. Invest. Dermatol.201113191853186010.1038/jid.2011.13921654831
     [Google Scholar]
  23. RendonA. SchäkelK. Psoriasis Pathogenesis and Treatment.Int. J. Mol. Sci.2019206147510.3390/ijms2006147530909615
     [Google Scholar]
  24. JangD. LeeA.H. ShinH.Y. SongH.R. ParkJ.H. KangT.B. LeeS.R. YangS.H. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.Int. J. Mol. Sci.2021225271910.3390/ijms2205271933800290
     [Google Scholar]
  25. VictorF.C. GottliebA.B. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis.J. Drugs Dermatol.20021326427512851985
     [Google Scholar]
  26. MostafaA. SabryD. AboraiaN. FawzyA. Abou-ElallaA.A. Dyslipidemia initiates keratinocytes proliferation through upregulation of lncRNA NEAT in psoriasis patients.Mol. Biol. Rep.20235097597760410.1007/s11033‑023‑08527‑w37531036
     [Google Scholar]
  27. ScheauC. BadarauI.A. MihaiL.G. ScheauA.E. CostacheD.O. ConstantinC. CalinaD. CaruntuC. CostacheR.S. CaruntuA. Cannabinoids in the Pathophysiology of Skin Inflammation.Molecules202025365210.3390/molecules2503065232033005
     [Google Scholar]
  28. GargT. RathG. GoyalA.K. Ancient and advanced approaches for the treatment of an inflammatory autoimmune disease-psoriasis.Crit. Rev. Ther. Drug Carrier Syst.201431433136410.1615/CritRevTherDrugCarrierSyst.201401012225072198
     [Google Scholar]
  29. GendrischF. HaarhausB. KriegerN. QuirinK.W. SchemppC.M. WölfleU. The Effect of Herbal Medicinal Products on Psoriasis-Like Keratinocytes.Biomolecules202111337110.3390/biom1103037133801280
     [Google Scholar]
  30. AlkhatibB. AlhiloS. AlhiloI. Psoriasis Management Using Herbal Supplementation: A Retrospective Clinical Case Study.Altern. Ther. Health Med.202329427027334144535
     [Google Scholar]
  31. HoffmannJ. GendrischF. SchemppC.M. WölfleU. New Herbal Biomedicines for the Topical Treatment of Dermatological Disorders.Biomedicines2020822710.3390/biomedicines802002732046246
     [Google Scholar]
  32. DengS. MayB.H. ZhangA.L. LuC. XueC.C.L. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis.Br. J. Dermatol.2013169476978210.1111/bjd.1255723909714
     [Google Scholar]
  33. ZhangS. WangJ. LiuL. SunX. ZhouY. ChenS. LuY. CaiX. HuM. YanG. MiaoX. LiX. Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms.Front. Pharmacol.20221390316010.3389/fphar.2022.90316036120325
     [Google Scholar]
  34. ElkhawagaO.Y. ElletyM.M. MoftyS.O. GhanemM.S. MohamedA.O. Review of natural compounds for potential psoriasis treatment.Inflammopharmacology20233131183119810.1007/s10787‑023‑01178‑036995575
     [Google Scholar]
  35. SánchezM. González-BurgosE. IglesiasI. Gómez-SerranillosM.P. Pharmacological Update Properties of Aloe Vera and its Major Active Constituents.Molecules2020256132410.3390/molecules2506132432183224
     [Google Scholar]
  36. SarasatiA. SyahruddinM.H. NuryantiA. AnaI.D. BarlianA. WijayaC.H. RatnadewiD. WunguT.D.K. TakemoriH. Plant-Derived Exosome-like Nanoparticles for Biomedical Applications and Regenerative Therapy.Biomedicines2023114105310.3390/biomedicines1104105337189671
     [Google Scholar]
  37. TaheriY. QuispeC. Herrera-BravoJ. Sharifi-RadJ. EzzatS.M. MerghanyR.M. ShaheenS. AzmiL. Prakash MishraA. SenerB. KılıçM. SenS. AcharyaK. NasiriA. Cruz-MartinsN. Tsouh FokouP.V. YdyrysA. BassygarayevZ. DaştanS.D. AlshehriM.M. CalinaD. ChoW.C. Urtica dioica-Derived Phytochemicals for Pharmacological and Therapeutic Applications.Evid. Based Complement. Alternat. Med.2022202213010.1155/2022/402433135251206
     [Google Scholar]
  38. CassanoN. MantegazzaR. BattagliniS. ApruzziD. LoconsoleF. VenaG.A. Adjuvant role of a new emollient cream in patients with palmar and/or plantar psoriasis: a pilot randomized open-label study.G. Ital. Dermatol. Venereol.2010145678979221139557
     [Google Scholar]
  39. El MihyaouiA. Esteves da SilvaJ.C.G. CharfiS. Candela CastilloM.E. LamartiA. ArnaoM.B. Chamomile (Matricaria chamomilla L.): A review of ethnomedicinal use, phytochemistry and pharmacological uses.Life (Basel)202212447910.3390/life1204047935454969
     [Google Scholar]
  40. MahmoudzadehE. NazemiyehH. HamedeyazdanS. Anti-inflammatory properties of the genus Symphytum L.: A Review.Iran. J. Pharm. Res.2022211e12394910.5812/ijpr.12394936060906
     [Google Scholar]
  41. ReidC. GriffithsC. Psoriasis and Treatment: Past, Present and Future Aspects.Acta Derm. Venereol.20201003708010.2340/00015555‑338631971601
     [Google Scholar]
  42. FarahnikB. NakamuraM. SinghR.K. AbroukM. ZhuT.H. LeeK.M. JoseM.V. DaLovisioR. KooJ. BhutaniT. LiaoW. The Patient’s Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy.Dermatol. Ther. (Heidelb.)20166331532410.1007/s13555‑016‑0130‑927474030
     [Google Scholar]
  43. BakerH. PUVA therapy for psoriasis.J. R. Soc. Med.198477753753910.1177/0141076884077007016747975
     [Google Scholar]
  44. AsimS. AhmedS. SeharN.U. Psoralen-ultraviolet a treatment with Psoralen-ultraviolet B therapy in the treatment of psoriasis.Pak. J. Med. Sci.201329375876110.12669/pjms.293.262224353623
     [Google Scholar]
  45. BakshiH. NagpalM. SinghM. DhingraG.A. AggarwalG. Treatment of Psoriasis: A Comprehensive Review of Entire Therapies.Curr. Drug Saf.20201528210410.2174/22123911MTAziOTU8431994468
     [Google Scholar]
  46. WangL. YangX. YangC. GaoJ. ZhaoY. ChengC. ZhaoG. LiuS. The inhibition effect of cold atmospheric plasma-activated media in cutaneous squamous carcinoma cells.Future Oncol.201915549550510.2217/fon‑2018‑041930648877
     [Google Scholar]
  47. GareriC. BennardoL. De MasiG. Use of a new cold plasma tool for psoriasis treatment: A case report.SAGE Open Med Case Rep.202082050313X2092270910.1177/2050313X20922709
     [Google Scholar]
  48. MaedaK. ShinzatoT. NaotsukaM. UsudaM. SezakiR. NiwaT. KawaguchiS. SaitoA. YamanakaN. OhtaK. Plasma exchange for treatment of intractable psoriasis.Artif. Organs19837445045310.1111/j.1525‑1594.1983.tb04225.x6651584
     [Google Scholar]
  49. BaughJA. BucalaR. Mechanisms for modulating TNF alpha in immune and inflammatory disease.Curr Opin Drug Discov Devel.200145635650
     [Google Scholar]
  50. KaushikS.B. LebwohlM.G. Psoriasis: Which therapy for which patient.J. Am. Acad. Dermatol.2019801274010.1016/j.jaad.2018.06.05730017705
     [Google Scholar]
  51. SinghA. EaswariT.S. Recent Advances in Psoriasis Therapy: Trends and Future Prospects.Curr. Drug Targets202122151760177110.2174/138945012266621011810345533461464
     [Google Scholar]
  52. AgüeroR. WoodburyMJ. LeeK. JohnssonHJ. MerolaJF. ArmstrongAW. Interleukin (IL)-17 versus il-23 inhibitors: Which is better to treat patients with moderate-to-severe psoriasis and mild psoriatic arthritis in dermatology clinics?J Rheumatol.202350S2111310.3899/jrheum.2023‑0511
     [Google Scholar]
  53. WegerW. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Br J Pharmacol.2010160481082010.1111/j.1476‑5381.2010.00702.x
     [Google Scholar]
  54. BlauveltA. PappK.A. GriffithsC.E.M. RandazzoB. WasfiY. ShenY.K. LiS. KimballA.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial.J. Am. Acad. Dermatol.201776340541710.1016/j.jaad.2016.11.04128057360
     [Google Scholar]
  55. HausteinUF. RytterM. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment.J Eur Acad Dermatol Venereol.2000145382388
     [Google Scholar]
  56. ChiricozziA. CostanzoA. FargnoliM.C. MalagoliP. PiasericoS. AmerioP. ArgenzianoG. BalatoN. BardazziF. BianchiL. CarreraC.G. ContiA. DapavoP. De SimoneC. LoconsoleF. Lo SchiavoA. MalaraG. MusumeciM.L. ParodiA. PerisK. PrignanoF. RongiolettiF. TalamontiM. PotenzaC. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.Eur. J. Dermatol.202131131610.1684/ejd.2021.396533648915
     [Google Scholar]
  57. GerdesS. HoffmannM. AsadullahK. KorgeB. MortazawiD. KrügerN. PersonkeY. TaboriS. GomezM. WegnerS. KreimendahlF. TautF. SticherlingM. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study.J. Eur. Acad. Dermatol. Venereol.202539Suppl 13849.10.1111/jdv.1929637462295
     [Google Scholar]
  58. KoppuS. SinghR. KaurK. FeldmanS.R. Review of bimekizumab in the treatment of psoriasis.Hum. Vaccin. Immunother.2022186211976710.1080/21645515.2022.211976736094828
     [Google Scholar]
  59. AliZ. MatthewsR. Al-JanabiA. WarrenR.B. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.Expert Rev. Clin. Immunol.202117101073108110.1080/1744666X.2021.196774834384327
     [Google Scholar]
  60. ArmstrongA. FahrbachK. LeonardiC. AugustinM. NeupaneB. KazmierskaP. BettsM. FreitagA. KiriS. TaiebV. SlimM. GomezN.N. WarrenR.B. Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.Dermatol. Ther. (Heidelb.)20221281777179210.1007/s13555‑022‑00760‑835798920
     [Google Scholar]
  61. FreitasE. BlauveltA. TorresT. Bimekizumab for the Treatment of Psoriasis.Drugs202181151751176210.1007/s40265‑021‑01612‑z34623614
     [Google Scholar]
  62. ReichK. WarrenR.B. LebwohlM. GooderhamM. StroberB. LangleyR.G. PaulC. De CuyperD. VanvoordenV. MaddenC. CioffiC. PetersonL. BlauveltA. Bimekizumab versus Secukinumab in Plaque Psoriasis.N. Engl. J. Med.2021385214215210.1056/NEJMoa210238333891380
     [Google Scholar]
  63. LiS.J. Perez-ChadaL.M. MerolaJ.F. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.J. Psoriasis Psoriatic Arthritis201942708010.1177/247553031881085131093599
     [Google Scholar]
  64. TobinA.M. KirbyB. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.BioDrugs2005191475710.2165/00063030‑200519010‑0000615691217
     [Google Scholar]
  65. ChimaM. LebwohlM. TNF inhibitors for psoriasis.Semin. Cutan. Med. Surg.201837313414210.12788/j.sder.2018.03930215629
     [Google Scholar]
  66. YangH. CraigD. EpsteinD. BojkeL. LightK. BruceI.N. SculpherM. WoolacottN. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.PharmacoEconomics201230425727010.2165/11595920‑000000000‑0000022283690
     [Google Scholar]
  67. UrdanetaM. JethwaH. SultanR. AbrahamS. A review on golimumab in the treatment of psoriatic arthritis.Immunotherapy201791187188910.2217/imt‑2017‑006328838285
     [Google Scholar]
  68. ChimentiM.S. ConigliaroP. CasoF. CostaL. OrtolanA. TriggianeseP. TassoM. FontiG.L. LorenzinM.G. PerriconeR. RamondaR. Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement.Clin. Rheumatol.2022411758410.1007/s10067‑021‑05874‑634410550
     [Google Scholar]
  69. LeeW.K. KimG.W. ChoH.H. KimW.J. MunJ.H. SongM. KimH.S. KoH.C. KimM.B. KimB.S. Erythrodermic Psoriasis Treated with Golimumab: A Case Report.Ann. Dermatol.201527444644910.5021/ad.2015.27.4.44626273164
     [Google Scholar]
  70. GottliebA.B. Infliximab for psoriasis.J. Am. Acad. Dermatol.2003492Suppl.11211710.1016/S0190‑9622(03)01143‑512894134
     [Google Scholar]
  71. ArsiwalaS. Infliximab: Efficacy in psoriasis.Indian J. Dermatol. Venereol. Leprol.20137972510.4103/0378‑6323.11552523974692
     [Google Scholar]
  72. SubediS. GongY. ChenY. ShiY. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.Drug Des. Devel. Ther.2019132491250210.2147/DDDT.S20014731413544
     [Google Scholar]
  73. BarkerJ. HoffmannM. WozelG. OrtonneJP. ZhengH. van HoogstratenH. ReichK. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).Br J Dermatol.2011165511091117
     [Google Scholar]
  74. LeonardiC.L. PowersJ.L. MathesonR.T. GoffeB.S. ZitnikR. WangA. GottliebA.B. Etanercept as monotherapy in patients with psoriasis.N. Engl. J. Med.2003349212014202210.1056/NEJMoa03040914627786
     [Google Scholar]
  75. SterryW. OrtonneJ.P. KirkhamB. BrocqO. RobertsonD. PedersenR.D. EstojakJ. MoltaC.T. FreundlichB. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.BMJ2010340feb02 2c14710.1136/bmj.c14720124563
     [Google Scholar]
  76. OnsunN. GüneşB. YabacıA. Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center.Dermatol. Ther.2021341e1462310.1111/dth.1462333274541
     [Google Scholar]
  77. GordonK. KormanN. FrankelE. WangH. JahreisA. ZitnikR. ChangT. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.J. Am. Acad. Dermatol.2006543Suppl. 2S101S11110.1016/j.jaad.2005.11.108816488320
     [Google Scholar]
  78. FerreiraM. BarreirosL. SegundoM.A. TorresT. SeloresM. Costa LimaS.A. ReisS. Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management.Colloids Surf. B Biointerfaces2017159232910.1016/j.colsurfb.2017.07.08028779637
     [Google Scholar]
  79. ChangY.S. LeeH.T. ChenW.S. HsiaoK.H. ChenM.H. TsaiC.Y. ChouC.T. Treatment of psoriasis with rituximab.J. Am. Acad. Dermatol.2012665e184e18510.1016/j.jaad.2010.08.00722507592
     [Google Scholar]
  80. CroS. SmithC. WilsonR. CorneliusV. Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial.Trials201819153410.1186/s13063‑018‑2914‑y30285894
     [Google Scholar]
  81. NoisetteA. HochbergM. Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives.Psoriasis (Auckl.)20188313910.2147/PTT.S14607630035098
     [Google Scholar]
  82. WuJ.J. ValdecantosW.C. Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide.J. Drugs Dermatol.201716877979028809993
     [Google Scholar]
  83. KeatingG.M. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.Drugs201777445947210.1007/s40265‑017‑0709‑128213862
     [Google Scholar]
  84. BlauveltA. KimballA.B. AugustinM. OkuboY. WitteM.M. CaprilesC.R. SontagA. AroraV. OsuntokunO. StroberB. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).Br. J. Dermatol.2022187686687710.1111/bjd.2174335791755
     [Google Scholar]
  85. RosmarinD.M. LebwohlM. ElewskiB.E. GottliebA.B. National Psoriasis Foundation Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.J. Am. Acad. Dermatol.201062583885310.1016/j.jaad.2009.05.01719932926
     [Google Scholar]
  86. TorsekarR. GautamM. Topical therapies in psoriasis.Indian Dermatol. Online J.20178423524510.4103/2229‑5178.20962228761838
     [Google Scholar]
  87. SegaertS. Calzavara-PintonP. de la CuevaP. JaliliA. Lons DanicD. PinkA.E. ThaçiD. GooderhamM. Long-term topical management of psoriasis: the road ahead.J. Dermatolog. Treat.202233111112010.1080/09546634.2020.172933532091278
     [Google Scholar]
  88. LawsP.M. YoungH.S. Topical treatment of psoriasis.Expert Opin. Pharmacother.201011121999200910.1517/14656566.2010.49277820569091
     [Google Scholar]
  89. Mohd NordinU.U. AhmadN. SalimN. Mohd YusofN.S. Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects.RSC Advances20211146290802910110.1039/D1RA06087B35478537
     [Google Scholar]
  90. ChenL. DengH. CuiH. FangJ. ZuoZ. DengJ. LiY. WangX. ZhaoL. Inflammatory responses and inflammation-associated diseases in organs.Oncotarget2018967204721810.18632/oncotarget.2320829467962
     [Google Scholar]
  91. LowesM.A. Suárez-FariñasM. KruegerJ.G. Immunology of Psoriasis.Annu. Rev. Immunol.201432122725510.1146/annurev‑immunol‑032713‑12022524655295
     [Google Scholar]
  92. JiaH.J. rui BaiS. XiaJ. yue HeS. DaiQ. ZhouM. WangX. Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity.Int. Immunopharmacol.202311911020510.1016/j.intimp.2023.11020537104917
     [Google Scholar]
  93. ChingT.T. ChiangW.C. ChenC.S. HsuA.L. Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity.Aging Cell201110350651910.1111/j.1474‑9726.2011.00688.x21348927
     [Google Scholar]
  94. OrhanH. DoğruerD.S. ÇakirB. ŞahinG. ŞahinM.F. The in vitro effects of new non-steroidal antiinflammatory compounds on antioxidant system of human erythrocytes.Exp. Toxicol. Pathol.1999514-539740210.1016/S0940‑2993(99)80028‑110445404
     [Google Scholar]
  95. MilosheskaD. RoškarR. Use of retinoids in topical antiaging treatments: A focused review of clinical evidence for conventional and nanoformulations.Adv. Ther.202239125351537510.1007/s12325‑022‑02319‑736220974
     [Google Scholar]
  96. HornEJ. DommS. KatzHI. LebwohlM. MrowietzU. KragballeK. International psoriasis council. Topical corticosteroids in psoriasis: strategies for improving safety.J Eur Acad Dermatol Venereol.2010242119124
     [Google Scholar]
  97. StaceyS.K. McEleneyM. Topical corticosteroids: Choice and application.Am. Fam. Physician2021103633734333719380
     [Google Scholar]
  98. ChoiE. ChandranN.S. TanC. Corticosteroid phobia: a questionnaire study using TOPICOP score.Singapore Med. J.202061314915310.11622/smedj.201911032488277
     [Google Scholar]
  99. SongS.Y. JungS.Y. KimE. Steroid phobia among general users of topical steroids: a cross-sectional nationwide survey.J. Dermatolog. Treat.201930324525010.1080/09546634.2018.150881730081700
     [Google Scholar]
  100. CastelaE. ArchierE. DevauxS. GalliniA. AractingiS. CribierB. JullienD. AubinF. BachelezH. JolyP. Le MaîtreM. MiseryL. RichardM.A. PaulC. OrtonneJ.P. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities.J. Eur. Acad. Dermatol. Venereol.201226s3Suppl. 3364610.1111/j.1468‑3083.2012.04522.x22512679
     [Google Scholar]
  101. Al-DhubaibiM.S. Association between Vitamin D deficiency and psoriasis: An exploratory study.Int. J. Health Sci. (Qassim)2018121333929623015
     [Google Scholar]
  102. KragballeK. Vitamin D analogues in the treatment of psoriasis.J. Cell. Biochem.1992491465210.1002/jcb.2404901091644854
     [Google Scholar]
  103. SatakeK. AmanoT. OkamotoT. Calcipotriol and betamethasone dipropionate synergistically enhances the balance between regulatory and proinflammatory T cells in a murine psoriasis model.Sci. Rep.2019911632210.1038/s41598‑019‑52892‑131705000
     [Google Scholar]
  104. KerkhofP. BarkerJ. GriffithsC.E.M. MenterA. LeonardiC. YoungM. KemenyL. PincelliC. BachelezH. KatsambasA. StåhleM. HornE.J. SterryW. International Psoriasis Council Improving clinical trial design in psoriasis: Perspectives from the global dermatology community.J. Dermatolog. Treat.201122418719310.3109/09546634.2010.48788820887207
     [Google Scholar]
  105. SmithN. WeymannA. TauskF.A. GelfandJ.M. Complementary and alternative medicine for psoriasis: A qualitative review of the clinical trial literature.J. Am. Acad. Dermatol.200961584185610.1016/j.jaad.2009.04.02919664846
     [Google Scholar]
  106. MerolaJ.F. HusniM.E. QureshiA.A. Psoriatic arthritis screening tools: study design and methodological challenges.Br. J. Dermatol.2014170499499510.1111/bjd.1281524400947
     [Google Scholar]
  107. CarrascosaJM. de la CuevaP. AraM. PuigL. BordasX. CarreteroG. FerrándizL. Sánchez-CarazoJL. DaudénE. López-EstebaranzJL. VidalD. HerranzP. JorqueraE. Coto-SeguraP. RiberaM. Methotrexate in moderate to severe psoriasis: Review of the literature and expert recommendations.Actas Dermosifiliogr.2016107319420610.1016/j.ad.2015.10.005
     [Google Scholar]
  108. AickaraD. BashyamA.M. PichardoR.O. FeldmanS.R. Topical methotrexate in dermatology: a review of the literature.J. Dermatolog. Treat.202233151251710.1080/09546634.2020.177017032412810
     [Google Scholar]
  109. SinghS.K. SingnarpiS.R. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.Indian J. Dermatol. Venereol. Leprol.202187221422210.25259/IJDVL_613_1933769732
     [Google Scholar]
  110. ChambersE.S. Vukmanovic-StejicM. Skin barrier immunity and ageing.Immunology2020160211612510.1111/imm.1315231709535
     [Google Scholar]
  111. Jansen van RensburgS. FrankenA. Du PlessisJ.L. Measurement of transepidermal water loss, stratum corneum hydration and skin surface pH in occupational settings: A review.Skin Res. Technol.201925559560510.1111/srt.1271131111588
     [Google Scholar]
  112. MüllerR.H. MäderK. GohlaS. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.Eur. J. Pharm. Biopharm.200050116117710.1016/S0939‑6411(00)00087‑410840199
     [Google Scholar]
  113. ZhangY. YanJ. LiZ. ZhengJ. SunQ. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate psoriasis-like skin inflammation.J. Interferon Cytokine Res.202242181810.1089/jir.2021.014635041513
     [Google Scholar]
  114. Aytar ÇelikP. DerkuşB. ErdoğanK. BarutD. Blaise MangaE. YıldırımY. PechaS. ÇabukA. Bacterial membrane vesicle functions, laboratory methods, and applications.Biotechnol. Adv.20225410786910.1016/j.biotechadv.2021.10786934793882
     [Google Scholar]
  115. CampanatiA. MaraniA. MartinaE. DiotalleviF. RadiG. OffidaniA. Psoriasis as an immune-mediated and inflammatory systemic disease: From pathophysiology to novel therapeutic approaches.Biomedicines2021911151110.3390/biomedicines911151134829740
     [Google Scholar]
  116. Genetics.Available from:https://ghr.nlm.nih.gov/primer/therapy/genetherapy(accessed on 2-7-2024)
  117. HegdeV. HickersonR.P. NainamalaiS. CampbellP.A. SmithF.J.D. McLeanW.H.I. Leslie PedrioliD.M. In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation.J. Control. Release201419635536210.1016/j.jconrel.2014.10.02225449884
     [Google Scholar]
  118. SeetharamanR. MahmoodA. KshatriyaP. PatelD. SrivastavaA. Mesenchymal Stem Cell Conditioned Media Ameliorate Psoriasis Vulgaris: A Case Study.Case Rep. Dermatol. Med.201920191510.1155/2019/830910331186972
     [Google Scholar]
  119. Owczarczyk-SaczonekA. Krajewska-WłodarczykM. KruszewskaA. PlacekW. MaksymowiczW. WojtkiewiczJ. Stem Cells as Potential Candidates for Psoriasis Cell-Replacement Therapy.Int. J. Mol. Sci.20171810218210.3390/ijms1810218229053579
     [Google Scholar]
  120. AgrawalY.O. MahajanU.B. MahajanH.S. OjhaS. Methotrexate-loaded nanostructured lipid carrier gel alleviates imiquimod-induced psoriasis by moderating inflammation: Formulation, optimization, characterization, in-vitro and in-vivo studies.Int. J. Nanomedicine2020154763477810.2147/IJN.S24700732753865
     [Google Scholar]
  121. WollinaU. TirantM. VojvodicA. LottiT. Treatment of Psoriasis: Novel Approaches to Topical Delivery.Open Access Maced. J. Med. Sci.20197183018302510.3889/oamjms.2019.41431850114
     [Google Scholar]
  122. ViegasJ.S.R. PraçaF.G. CaronA.L. SuzukiI. SilvestriniA.V.P. MedinaW.S.G. Del CiampoJ.O. KraviczM. BentleyM.V.L.B. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis.Drug Deliv. Transl. Res.202010364666010.1007/s13346‑020‑00723‑632060883
     [Google Scholar]
  123. TrombinoS. MellaceS. CassanoR. Solid lipid nanoparticles for antifungal drugs delivery for topical applications.Ther. Deliv.20167963964710.4155/tde‑2016‑004027582235
     [Google Scholar]
  124. Abu HashimI. Abo El-MagdN. El-SheakhA. HamedM. Abd El-GawadA.E.G. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo–in vivo evaluation study.Int. J. Nanomedicine2018131059107910.2147/IJN.S15641229503541
     [Google Scholar]
  125. DoppalapudiS. JainA. ChopraD.K. KhanW. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.Eur. J. Pharm. Sci.20179651552910.1016/j.ejps.2016.10.02527777066
     [Google Scholar]
  126. KommineniN. PaulD. SakaR. KhanW. NanjappanS. Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics.Nanotheranostics20226442443510.7150/ntno.7637036051857
     [Google Scholar]
  127. ChenJ. MaY. TaoY. ZhaoX. XiongY. ChenZ. TianY. Formulation and evaluation of a topical liposomal gel containing a combination of zedoary turmeric oil and tretinoin for psoriasis activity.J. Liposome Res.202131213014410.1080/08982104.2020.174864632223352
     [Google Scholar]
  128. KumarR. DograS. AmarjiB. SinghB. KumarS. Sharma VinayK. MahajanR. KatareO.P. Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis.JAMA Dermatol.2016152780781510.1001/jamadermatol.2016.085927096709
     [Google Scholar]
  129. MengS. SunL. WangL. LinZ. LiuZ. XiL. WangZ. ZhengY. Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity.Colloids Surf. B Biointerfaces201918211035210.1016/j.colsurfb.2019.11035231306831
     [Google Scholar]
  130. FathallaD. YoussefE.M.K. SolimanG.M. Liposomal and Ethosomal Gels for the Topical Delivery of Anthralin: Preparation, Comparative Evaluation and Clinical Assessment in Psoriatic Patients.Pharmaceutics202012544610.3390/pharmaceutics1205044632403379
     [Google Scholar]
  131. Clinicaltrials.gov.Available from: https://clinicaltrials.gov/ct2/results?cond=psoriasis&term=&cntry=&state=&city=&dist(accessed on 7-7-2024)
/content/journals/raiad/10.2174/0127722708300943240724051518
Loading
Comprehensive Insights into Psoriasis: Pathophysiology, An Advanced Exploration of Current Landscape and Future Prospects in "Therapeutic Strategies"
Rec Adv Inflamm Allergy Drug Discov 19, 158 (2025); https://doi.org/10.2174/0127722708300943240724051518
/content/journals/raiad/10.2174/0127722708300943240724051518
/content/journals/raiad/10.2174/0127722708300943240724051518
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): biological therapies; Interleukins inhibitors; novel therapeutic approaches; plasma therapies; Psoriasis pathophysiology; TNF-α inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test